CTSU E3F05: Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
March 30, 2010
Cancer - Brain
Principal Investigator: Robert A Chapman, MD
The purpose of this study is to determine whether the addition of temozolomide to radiation improves survival of patients with low grade gliomas.
Patients must have pathological diagnosis of astrocytoma grade 2, oligodendroglioma grade 2, or oligoastrocytoma grade 2; Patients must have paraffin-embedded tumor specimen available for submission for confirmation of pathological diagnosis and determination of 1p/19q deletion status; Patients must be greater than or equal to 40 years old